Protective effect of selegiline in the early and late phases of Parkinson's disease.
Csanda
E
E
Institute of Neurology, Semmelweis Medical School, Budapest, Hungary.
Tárczy
M
M
D000367:Age Factors; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000008:administration & dosage* / Q000009:adverse effects
D012642:Selegiline; D007980:Levodopa